The therapeutic platform comprises a novel proprietary and IP-protected approach, which includes utilisation of a bacterial danger signal in combination with the patient’s tumour antigens to mobilise the patients’ immune system and thus combat the disease.
The company’s technology lays emphasis on dendritic cells (DCs), which primarily regulate the immune system.
The vaccine, which was initially meant for aggressive brain cancer, will be applicable to all types of cancerous diseases.
Results from multi-centre phase II clinical study are likely to be announced in 2012.